|
Basic Characteristics of Mutations
|
|
Mutation Site
|
C325Y |
|
Mutation Site Sentence
|
TABLE 1 |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
UL56 |
|
Standardized Encoding Gene
|
UL56
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
MF871618.1
|
|
Functional Impact and Mechanisms
|
|
Disease
|
Cytomegalovirus infections
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
Y |
|
Treatment
|
Letermovir |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
37902387
|
|
Title
|
Real-life experience in two cases of secondary prophylaxis with letermovir for CMV infection in solid organ transplantation
|
|
Author
|
Perez A-B,Santos Bravo M,Vidal-Verdu E,Paez-Vega A,Vaquero-Barrios J-M,Montero J-L,Marcos M-A,Torre-Cisneros J
|
|
Journal
|
Microbiology spectrum
|
|
Journal Info
|
2023 Dec 12;11(6):e0163023
|
|
Abstract
|
This observation provides comprehensive data on the clinical correlates of both cytomegalovirus (CMV) genotypic follow-up and clinical monitoring and outcomes for two different solid organ transplantation recipients that received letermovir as secondary prophylaxis. Our study emphasizes that monitoring of CMV disease in the patient and early genotypic detection of resistance mutations are essential when using new antiviral drugs for off-label indication in patients experiencing CMV relapses or not responding to standard antiviral therapy. These cases and the bibliography reviewed can be helpful for other researchers and clinicians working in the field to optimize the use of new treatments for transplant recipients since drug-resistant CMV infection is an important emerging problem even with new developments in antiviral treatment.
|
|
Sequence Data
|
-
|